Research Paper Volume 13, Issue 4 pp 5284—5296

Matrix stiffness promotes glioma cell stemness by activating BCL9L/Wnt/β-catenin signaling

Greater matrix stiffness promoted stemness in glioma. (A) Tissue stiffness of tumors derived from the high-degree/malignant (HD) and low-degree/innocent (LD) groups. (B) The relative proliferation of LN229 or T98G cells pre-cultured on gels of different stiffness levels was detected at various time points. (C) Tumor volumes of mice injected with LN229 or T98G cells pre-cultured on gels of different stiffness levels. (D) The relative number of cell colonies formed by LN229 or T98G cells pre-cultured on gels of different stiffness levels was detected at various time points. (E) Tumorigenesis of mice subcutaneously injected with 104 LN229 or T98G cells pre-cultured on gels of different stiffness levels. (F) Flow cytometry analysis of CD133 expression in LN229 or T98G cells cultured on gels of different stiffness levels. (G) Flow cytometry analysis of CD133 expression in tissues derived from the HS and LS groups. (H) Immunofluorescence analysis of CD133 expression in tissues derived from the HS and LS groups. Scale bar, 50 μm. (I) Kaplan-Meier analysis of CD133 mRNA expression in patients from The Cancer Genome Atlas database (N=675). (J) Kaplan-Meier analysis of CD133 mRNA expression in patients from the Chinese Glioma Genome Atlas database (N=325). *P

Figure 1. Greater matrix stiffness promoted stemness in glioma. (A) Tissue stiffness of tumors derived from the high-degree/malignant (HD) and low-degree/innocent (LD) groups. (B) The relative proliferation of LN229 or T98G cells pre-cultured on gels of different stiffness levels was detected at various time points. (C) Tumor volumes of mice injected with LN229 or T98G cells pre-cultured on gels of different stiffness levels. (D) The relative number of cell colonies formed by LN229 or T98G cells pre-cultured on gels of different stiffness levels was detected at various time points. (E) Tumorigenesis of mice subcutaneously injected with 104 LN229 or T98G cells pre-cultured on gels of different stiffness levels. (F) Flow cytometry analysis of CD133 expression in LN229 or T98G cells cultured on gels of different stiffness levels. (G) Flow cytometry analysis of CD133 expression in tissues derived from the HS and LS groups. (H) Immunofluorescence analysis of CD133 expression in tissues derived from the HS and LS groups. Scale bar, 50 μm. (I) Kaplan-Meier analysis of CD133 mRNA expression in patients from The Cancer Genome Atlas database (N=675). (J) Kaplan-Meier analysis of CD133 mRNA expression in patients from the Chinese Glioma Genome Atlas database (N=325). *P < 0.05, **P < 0.01, n.s. no significant difference.